These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36198436)

  • 1. Frequency of GLP-1 receptor agonists use in diabetic patients diagnosed with delayed gastric emptying and their demographic profile.
    Kalas MA; Dang TQ; Galura G; Alvarado L; Dwivedi AK; Deoker A; McCallum R
    J Investig Med; 2023 Jan; 71(1):11-16. PubMed ID: 36198436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions.
    Beti C; Stratmann B; Bokman G; Dreier J; Hauber M; Lee-Barkey YH; Fischer M; Knabbe C; Tschoepe D
    Horm Metab Res; 2019 Apr; 51(4):267-273. PubMed ID: 30690693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric electrical stimulation: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(16):1-79. PubMed ID: 23074486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.
    Lembo A; Camilleri M; McCallum R; Sastre R; Breton C; Spence S; White J; Currie M; Gottesdiener K; Stoner E;
    Gastroenterology; 2016 Jul; 151(1):87-96.e6. PubMed ID: 27055601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
    Foer D; Beeler PE; Cui J; Karlson EW; Bates DW; Cahill KN
    Am J Respir Crit Care Med; 2021 Apr; 203(7):831-840. PubMed ID: 33052715
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
    Maselli DB; Camilleri M
    Adv Exp Med Biol; 2021; 1307():171-192. PubMed ID: 32077010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence.
    Tsai SF; Chen CH
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
    Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma.
    Sterling J; Hua P; Dunaief JL; Cui QN; VanderBeek BL
    Br J Ophthalmol; 2023 Feb; 107(2):215-220. PubMed ID: 34413054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
    Al Batran R; Almutairi M; Ussher JR
    Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
    Maida A; Lovshin JA; Baggio LL; Drucker DJ
    Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus.
    Halland M; Bharucha AE
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):929-36. PubMed ID: 26717862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor action in the vasculature.
    Almutairi M; Al Batran R; Ussher JR
    Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
    Werner U
    J Diabetes Complications; 2014; 28(1):110-4. PubMed ID: 23992745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
    Milder DA; Milder TY; Liang SS; Kam PCA
    Anaesthesia; 2024 Jul; 79(7):735-747. PubMed ID: 38740566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.